The FDA has accused Amylin (AMLN) of hiding a study that raised worries over heart safety...

|By:, SA News Editor

The FDA has accused Amylin (AMLN) of hiding a study that raised worries over heart safety related to the firm's Byetta diabetes treatment, and then stonewalling the agency when it learned about the concerns. Amylin later misled investors by not disclosing that the study played a key role in the FDA rejecting the company's follow-on diabetes drug Bydureon.